Rockefeller Capital Management
NGM

Rockefeller Capital Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Rockefeller Capital Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000
Closed -$5K – 4066
2022
Q4 		$5K Hold
1,000
– – ﹤0.01% 3354
2022
Q3 		$13K Hold
1,000
– – ﹤0.01% 2986
2022
Q2 		$12K Hold
1,000
– – ﹤0.01% 3043
2022
Q1 		$15K Buy
+1,000
New +$15.6K ﹤0.01% 2868

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Rockefeller Capital Management's NGM Position: Q1 2023 in Review

Rockefeller Capital Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2023, closing a stake of 1,000 shares — an estimated $5K sold.

Rockefeller Capital Management first reported a position in NGM in Q1 2022 and held it in 4 quarters. The position peaked at $15K in Q1 2022. 122 funds tracked by Wall St. Rank hold NGM as of Q1 2023.

  • Rockefeller Capital Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 1,000 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $5K.
  • Rockefeller Capital Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
  • Rockefeller Capital Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $15K in Q1 2022.
  • 122 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.